市場調查報告書

抗發炎藥的全球市場:成長,趨勢,及預測

Anti Inflammatory Drugs Market - Growth, Trends, and Forecast (2020 - 2025)

出版商 Mordor Intelligence LLP 商品編碼 921256
出版日期 內容資訊 英文 112 Pages
商品交期: 2-3個工作天內
價格
抗發炎藥的全球市場:成長,趨勢,及預測 Anti Inflammatory Drugs Market - Growth, Trends, and Forecast (2020 - 2025)
出版日期: 2020年01月01日內容資訊: 英文 112 Pages
簡介

抗發炎藥,用於氣喘、關節炎、慢性阻塞性肺病(COPD)等疾病的治療。全球許多地區久坐的生活方式增加和空氣品質惡化伴隨的關節炎及呼吸系統相關疾病的盛行率增加,是推動抗發炎藥市場成長的主要原因。暢銷藥物的副作用和專利到期抑制市場成長,不過,抗發炎性生物製藥,免疫選擇性抗發炎性衍生物(ImmSAID)等新研究的發展,盡可能使該級的藥物沒有副作用,使維持藥物的有效性和效力成為可能。

本報告提供全球抗發炎藥市場的相關調查,市場機會和趨勢,成長及阻礙因素,各治療、藥物類別、銷售管道、地區的市場分析,競爭情形,主要企業的簡介等資訊。

目錄

第1章 簡介

  • 調查成果
  • 調查的前提條件
  • 調查範圍

第2章 調查手法

第3章 摘要整理

第4章 市場動態

  • 市場概要
  • 市場成長要素
    • 自體免疫及呼吸疾病發生率的上升
    • 更安全的新的抗發炎藥的調查
  • 阻礙市場要素
    • 抗發炎藥的副作用
    • 專利的有效期限
  • 波特的五力分析

第5章 市場區隔

  • 各治療
    • 關節炎
    • 慢性阻塞性肺病(COPD)
    • 多發性硬化症
    • 發炎性腸道疾病(IBD)
    • 氣喘
    • 肌腱炎
    • 其他
  • 各類藥物
    • 抗發炎性生技藥品
    • 非類固醇消炎劑(NSAIDS)
    • 皮質類固醇
    • 免疫選擇的抗發炎衍生物(ImSAID)
    • 其他
  • 各銷售管道
    • 處方
    • 商店(OTC)
  • 各地區
    • 北美
    • 歐洲
    • 亞太地區
    • 中東、非洲
    • 南美

第6章 競爭情形

  • 企業簡介
    • Pfizer Inc.
    • Amgen Inc.
    • GlaxoSmithKline PLC
    • Johnson & Johnson
    • Novartis International AG
    • F. Hoffmann-La Roche AG
    • AbbVie Inc
    • AstraZeneca PLC
    • Merck & Company, Inc.
    • Eli Lily and Company

第7章 市場機會及今後趨勢

目錄
Product Code: 66689

Market Overview

Anti-inflammatory drugs are used to treat conditions like Asthma, Arthritis, Chronic obstructive pulmonary disease (COPD) and other diseases. Increasing the prevalence of these diseases is the major factor propelling the market upwards. Although documented incidences of side effects and patent expiration of Blockbuster drugs are restraining the market growth, new research advancements in Anti Inflammatory Biologics, Immune Selective Anti-Inflammatory Derivatives (ImSAIDs), etc. are helping to make this class of drugs as side effect free as possible, maintaining the efficacy and potency of the drug.

Scope of the Report

Anti-inflammatory drugs help suppress the inadvertent alarm, the immune system triggers against body cells, which causes inflammation in the various body part. With increasing sedentary lifestyle and deteriorating air quality in many parts of the world, the prevalence of arthritis and respiratory-related diseases are on the rise. Hence, there has been an increase in the Anti-inflammatory drugs market in the past decade, and the trend seems to only increase with a much healthier rate. The market is segmented by treatment, drug class, sales channel, and geography.

Key Market Trends

Anti Inflammatory drugs for Arthritis Treatment dominate the Market

Arthritis is the inflammation in the joints. There are different types of arthritis, osteoarthritis and rheumatoid arthritis being the most common among them. Symptoms of Arthritis develop over time, but they may appear suddenly as well. Arthritis is more prevalent in the geriatric population, but there have been some documented cases of arthritis in children as well. Other common forms of arthritis include psoriatic arthritis, fibromyalgia, and gout.

Osteoarthritis is caused due to the breakdown of protective cartilage, causing pain and movement of joints difficult. Non-steroidal Anti-Inflammatory Drugs (NSAIDs) like diclofenac, ibuprofen, and naproxen have been proven to be very effective in suppressing the pain from Osteoarthritis but may cause side effects like stomach upset, cardiovascular problems, bleeding problems, and liver and kidney damage. NSAID gels have also been proven to alleviate the pain and have lesser side effects. Doctors have been turning towards prescribing the newest form of Anti-Inflammation drugs called Biologics.

The risk of arthritis has only increased in recent times due to an increase in the sedentary lifestyle, obesity, and unhealthy food habits. Hence, the drug market for its treatment will only see growth in the recent future.

North America dominates in Anti-Inflammatory drugs Market

North America is the largest market in the Anti-Inflammatory Drugs Market due to the factors such as established healthcare sector with a large number of renowned players, high investment & demand for more effective and safer drugs, etc. Moreover, the high income per capita, rise inpatient visits to physicians, research advancements due to high funding are some of the factors that are driving the growth of the North American market.

Competitive Landscape

Majority of the Anti-Inflammatory drugs are being manufactured by the global key players. Market leaders with more funds for research and a better distribution system have established their position in the market.

Reasons to Purchase this report:

  • The market estimate (ME) sheet in Excel format
  • Report customization as per the client's requirements
  • 3 months of analyst support

Table of Contents

1 INTRODUCTION

  • 1.1 Study Deliverables
  • 1.2 Study Assumptions
  • 1.3 Scope of the Study

2 RESEARCH METHODOLOGY

3 EXECUTIVE SUMMARY

4 MARKET DYNAMICS

  • 4.1 Market Overview
  • 4.2 Market Drivers
    • 4.2.1 Rising Incidences of Autoimmnue and Respiratory Conditions
    • 4.2.2 Research for Safer New Anti-Inflammatory Drugs
  • 4.3 Market Restraints
    • 4.3.1 Side Effects of Anti-Inflammtory Drugs
    • 4.3.2 Patent Expiration
  • 4.4 Porter's Five Force Analysis
    • 4.4.1 Threat of New Entrants
    • 4.4.2 Bargaining Power of Buyers/Consumers
    • 4.4.3 Bargaining Power of Suppliers
    • 4.4.4 Threat of Substitute Products
    • 4.4.5 Intensity of Competitive Rivalry

5 MARKET SEGMENTATION

  • 5.1 By Treatment
    • 5.1.1 Arthritis
    • 5.1.2 Chronic obstructive pulmonary disease (COPD)
    • 5.1.3 Multiple Sclerosis
    • 5.1.4 Inflammatory bowel disease (IBD)
    • 5.1.5 Asthma
    • 5.1.6 Tendonitis
    • 5.1.7 Other Treatments
  • 5.2 By Drug Class
    • 5.2.1 Anti-Inflammatory Biologics
    • 5.2.2 Nonsteroidal anti inflammatory drugs (NSAIDS)
    • 5.2.3 Corticosteroids
    • 5.2.4 Immune-selective anti-inflammatory derivative (ImSAID)
    • 5.2.5 Other Drug Classes
  • 5.3 By Sales Channel
    • 5.3.1 Prescription
    • 5.3.2 Over the Counter (OTC)
  • 5.4 Geography
    • 5.4.1 North America
      • 5.4.1.1 US
      • 5.4.1.2 Canada
      • 5.4.1.3 Mexico
    • 5.4.2 Europe
      • 5.4.2.1 Germany
      • 5.4.2.2 UK
      • 5.4.2.3 France
      • 5.4.2.4 Italy
      • 5.4.2.5 Spain
      • 5.4.2.6 Rest of Europe
    • 5.4.3 Asia Pacific
      • 5.4.3.1 China
      • 5.4.3.2 Japan
      • 5.4.3.3 India
      • 5.4.3.4 Australia
      • 5.4.3.5 South Korea
      • 5.4.3.6 Rest of Asia-Pacific
    • 5.4.4 Middle East and Africa
      • 5.4.4.1 GCC
      • 5.4.4.2 South Africa
      • 5.4.4.3 Rest of Middle East and Africa
    • 5.4.5 South America
      • 5.4.5.1 Brazil
      • 5.4.5.2 Argentina
      • 5.4.5.3 Rest of South America

6 COMPETITIVE LANDSCAPE

  • 6.1 Company Profiles
    • 6.1.1 Pfizer Inc.
    • 6.1.2 Amgen Inc.
    • 6.1.3 GlaxoSmithKline PLC
    • 6.1.4 Johnson & Johnson
    • 6.1.5 Novartis International AG
    • 6.1.6 F. Hoffmann-La Roche AG
    • 6.1.7 AbbVie Inc
    • 6.1.8 AstraZeneca PLC
    • 6.1.9 Merck & Company, Inc.
    • 6.1.10 Eli Lily and Company

7 MARKET OPPORTUNITIES AND FUTURE TRENDS